AIM ImmunoTech Inc. CEO Thomas K. Equels recently participated in a ‘Fireside Chat’ video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets.
During the Fireside Chat, Equels discussed recent accomplishments, key upcoming goals and milestones, as well as the financial and operational outlook for AIM’s business. Watch the video here.
Forward-Looking Statements And Cautionary Statements
The interview provided herewith contains forward-looking statements that involve a number of risks and uncertainties. Among other things, for those statements, AIM claims the protection of safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements made in this interview speak only as of the date of the interview. AIM does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. For example, significant additional testing and trials will be required to determine whether Ampligen will be effective in the treatment of COVID-19 in humans and no assurance can be given that it will be the case. Results obtained in animal models do not necessarily predict results in humans. Human clinical trials will be necessary to prove whether or not Ampligen will be efficacious in humans. No assurance can be given as to whether current or planned immuno-oncology clinical trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, AIM cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Some of the world’s largest pharmaceutical companies and medical institutions are racing to find a treatment for COVID-19.
Even if Ampligen proves effective in combating the virus, no assurance can be given that AIM’s actions toward proving this will be given first priority or that other treatments that eventually prove capable will not make AIM’s efforts ultimately unproductive. AIM recognizes that all cancer centers, like all medical facilities, must make the pandemic their priority. Therefore, there is the potential for delays in clinical trial enrollment and reporting in ongoing studies in cancer patients because of the COVID-19 medical emergency. No assurance can be given that future studies will not result in findings that are different from those reported in the studies referenced in the interview. No assurance can be given that patent applications will be granted. Operating in foreign countries carries with it a number of risks, including potential difficulties in enforcing intellectual property rights. AIM cannot assure that its potential foreign operations will not be adversely affected by these risks.
Please review the “Risk Factors” section in AIM’s latest annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. AIM’s SEC filings are available at www.aimimmuno.com. The information found on AIM’s website is not incorporated by reference into this interview and is included for reference purposes only.
The Interviewer, Ed Woo, is the Director of Research and a Senior Analyst at Ascendiant Capital Markets, LLC. Ascendiant Securities LLC, an affiliate of Ascendiant Capital Markets. Ascendiant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months. Full Analyst Certification and Disclosures can be found in the published research reports for the company (which can be requested at firstname.lastname@example.org).